Mycobacterium indicus pranii (Mw)-mediated protection against visceral leishmaniasis: Involvement of TLR4 signalling

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2892-2902

  Adhikari, Anupam ^a   Majumder, Saikat ^a   Banerjee, Sayantan ^a   Gupta, Gaurav ^a   Bhattacharya, Parna ^a   Majumdar, Suchandra Bhattacharyya ^a   Saha, Bhaskar ^b   Majumdar, Subrata ^a  

^a BOSE INSTITUTE   (India)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Amphotericin B; Arginase1; Cytokines; Macrophages; Nitric oxide

Indexed keywords

AMPHOTERICIN B; ANTILEISHMANIAL AGENT; ARGINASE 1; HEAT KILLED MYCOBACTERIUM INDICUS PRANII; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 10; INTERLEUKIN 12; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTIN POLYMERIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA BINDING; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MYCOBACTERIUM; MYCOBACTERIUM INDICUS PRANII; NONHUMAN; PARASITE SURVIVAL; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; VISCERAL LEISHMANIASIS;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; BLOTTING, WESTERN; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROSCOPY; MICROSCOPY, CONFOCAL; MYCOBACTERIUM; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PARASITE LOAD; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84869485281     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks315     Document Type: Article

References (43)

1. Dey R, Majumder N, Bhattacharyya S et al. Induction of host protective Th1 immune response by chemokines in Leishmania donovani-infected BALB/c mice. Scand J Immunol 2007; 66: 671-83.
2. Faria MS, Reis FC, Azevedo-Pereira RL et al. Leishmania inhibitor of serine peptidase 2 prevents TLR4 activation by neutrophil elastase promoting parasite survival in murine macrophages. J Immunol 2011; 186: 411-22.
3. Wanasen N, Soong L. l-Arginine metabolism and its impact on host immunity against Leishmania infection. Immunol Res 2008; 41: 15-25.
4. Modolell MI, Corraliza M, Link F et al. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow-derived macrophages by TH1 and TH2 cytokines. Eur J Immunol 1995; 25: 1101-4.
5. Iniesta V, Gomez-Nieto LC, Molano I et al. Arginase I induction in macrophages, triggered by Th2-type cytokines supports the growth of intracellular Leishmania parasites. Parasite Immunol 2002; 24: 113-8.
6. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 2000; 4: 158-77.
7. Reed SG, Coler RN, Campos-Neto A. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vaccines 2003; 2: 239-52.
8. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179: 1485-94.
9. Flynn B, Wang V, Sacks DL et al. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect Immun 2005; 73: 4948-54.
10. Underhill DM, Ozinsky A. Toll-like receptors: key mediators of microbe detection. Curr Opin Immunol 2002; 14: 103-10.
11. Netea MG, Van der Graaf C, Van der Meer JW et al. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 2004; 75: 749-55.
12. Kawahara T, Teshima S, Oka A et al. Type I Helicobacter pylori lipopolysaccharide stimulates Toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. Infect Immun 2001; 69: 4382-9.
13. Reddi PP, Amin AG, Khandekar PS et al. Molecular definition of unique species status of Mycobacterium w; a candidate leprosy vaccine strain. Int J Lepr Other Mycobact Dis 1994; 62: 229-36.
14. Zaheer SA, Mukherjee R, Ramkumar B et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 1993; 167: 401-10.
15. Gupta AN, Geetha J, Mani P et al. Immunogenicity and protective efficacy of "Mycobacterium w" against Mycobacterium tuberculosis in mice immunized with live versus heat-killed M. w by the aerosol or parenteral route. Infect Immun 2009; 77: 223-31.
16. Kharkar R. Immune recovery in HIV with Mycobacterium w. J Indian Med Assoc 2002; 100: 578-79.
17. Chaudhuri P, Mukhopadhyay S. Bladder preserving approach for muscle invasive bladder cancer-role of Mycobacterium w. J Indian Med Assoc 2003; 101: 559-60.
18. Razonable RR, Henault M, Lee LN et al. Secretion of proinflammatory cytokines and chemokines during amphotericin B exposure is mediated by co activation of toll-like receptors 1 and 2. Antimicrob Agents Chemother 2005; 49: 1617-21.
19. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998; 6: 1009-18.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
21. Hostetter JM, Steadham EM, Haynes JS et al. Cytokine effects on maturation of the phagosomes containing Mycobacteria avium subspecies paratuberculosis in J774 cells. FEMS Immunol Med Microbiol 2002; 34: 127-34.
22. Green LC, Wagner DA, Glogowski J et al. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 1982; 126: 131-8.
23. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4.
24. Majumdar S, Kane LH, Rossi MW et al. Protein kinase C isotypes and signal transduction in human neutrophils: selective substrate specificity of calcium dependent b-PKC and novel calcium independent n-PKC. Biochim Biophys Acta 1993; 1176: 276-86.
25. Ghosh S, Bhattacharyya S, Sirkar M et al. Leishmania donovani suppresses activator protein-1 and NF-kB in host macrophages via ceramide generation: involvement of extracellular signal-regulated kinase. Infect Immun 2002; 70: 6828-38.
26. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/ Th2 phenotype. J Immunol 1998; 160: 5347-54.
27. Bhattacharya P, Bhattacharjee S, Gupta G et al. Arabinosylated lipoarabinomannan-mediated protection in visceral leishmaniasis through up-regulation of Toll-like receptor 2 signaling: an immunoprophylactic approach. J Infect Dis 2010; 202: 145-55.
28. Chandra D, Naik S. Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage/ monocytic lineage by modulating MAPK pathways through a contact dependent mechanism. Clin Exp Immunol 2008; 154: 224-34.
29. Neal MD, Leaphart C, Levy R et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176: 3070-9.
30. Kobayashi KLD, Hernandez JE, Galan CA et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
31. Prive C, Descoteaux A. Leishmania donovani promastigotes evade the activation of mitogen-activated protein kinases p38, c-Jun N-terminal kinase and extracellular signal-regulated kinase-1/2 during infection of naive macrophages. Eur J Immunol 2000; 8: 2235-44.
32. Row R. The curative value of Leishmania culture "vaccine" in oriental sore. Br Med J 1912; 1: 540-1.
33. Afonso LC, Scharton TM, Vieira LQ et al. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263: 235-7.
34. Uzonna JE, Bretscher PA. Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice. Eur J Immunol 2001; 31: 3175-84.
35. Kropf P, Freudenberg MA, Modolell M et al. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect Immun 2004; 72: 1920-8.
36. Ribeiro-Gomes FL, Moniz-de-Souza MC, Alexandre-Moreira MS et al. Neutrophils activate macrophages for intracellular killing of Leishmania major through recruitment of TLR4 by neutrophil elastase. J Immunol 2007; 179: 3988-94.
37. Walker PS, Scharton-Kersten T, Krieg AM et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-gammadependent mechanisms. Proc Natl Acad Sci USA 1999; 96: 6970-5.
38. Verstak B, Nagpal K, Bottomley SP et al. MyD88 adapter-like (Mal)/ TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kB proinflammatory responses. J Biol Chem 2009; 284: 24192-203.
39. Mauel J, Ransijn A, Buchmuller-Rouiller Y. Killing of Leishmania parasites in activated murine macrophages is based on an L-arginine dependent process that produces nitrogen derivatives. J Leukoc Biol 1991; 49: 73-82.
40. Liew FY, Li Y, Millott S. Tumour necrosis factor (TNF-a) in leishmaniasis. II. TNF-a-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology 1990; 71: 556-9.
41. Murray HW, Hariprashad J. Interleukin 12 is effective treatment for an established systemic intracellular infection: experimental visceral leishmaniasis. J Exp Med 1995; 181: 387-91.
42. Barral-Netto M, Barral A, Brownell CE et al. Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 1992; 257: 545-8.
43. Mathur RK, Awasthi A, Wadhone P et al. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 2004; 10: 540-4.